Hidrasec (Racecadotril)

Hidrasec is indicated for the symptomatic treatment of acute diarrhea in adults and children when a non‑opioid antidiarrheal option is desired.

• Management of acute watery diarrhea caused by infections or dietary factors.
• Adjunct to oral rehydration therapy to reduce stool output.
• Use in travelers' diarrhea where rapid symptom control is needed.
• Suitable for patients who require limited systemic absorption.
• May be considered in short‑term treatment of diarrhea associated with mild gastrointestinal disturbances.

• Racecadotril exerts its antidiarrheal effect by inhibiting the enzyme enkephalinase (neutral endopeptidase) in the intestinal mucosa. This inhibition raises the local concentration of endogenous enkephalins, which activate opioid receptors on enteric neurons. The resulting activation reduces cyclic AMP‑mediated chloride secretion and slows intestinal motility, thereby decreasing fluid loss into the lumen and alleviating diarrheal symptoms. The action is confined to the gut, resulting in minimal systemic opioid effects.

Adverse reactions reported with racecadotril are generally mild, but rare serious events have been described.

Common

• Nausea or mild abdominal discomfort, usually transient.
• Headache of mild to moderate intensity.
• Dizziness, particularly when standing quickly.
• Temporary increase in stool frequency or loose stools during the first 1–2 days of therapy.

Serious

• Allergic skin reactions such as maculopapular rash or urticaria.
• Severe hypersensitivity manifestations including angioedema of the face or lips.
• Elevation of hepatic transaminases observed in isolated laboratory reports.
• Acute pancreatitis reported rarely, requiring immediate medical evaluation.

When considering Hidrasec, clinicians should evaluate several precautionary factors to ensure safe use.

• Use with caution in patients with known hypersensitivity to racecadotril or any excipients.
• Assess renal function before initiating therapy, as accumulation may occur in severe impairment.
• Monitor liver enzymes in patients with pre‑existing hepatic disease.
• Avoid use in infants younger than 3 months unless directed by a pediatric specialist.
• Consider alternative therapy for patients taking other antidiarrheal agents that act on opioid receptors.
• Pregnant or breastfeeding women should be evaluated individually due to limited safety data.

Racecadotril may interact with certain medications; awareness of these interactions helps prevent reduced efficacy or increased risk.

Avoid

• Concomitant use with potent opioid agonists (e.g., morphine, codeine) that may mask the drug’s antidiarrheal effect.
• Combination with other enkephalinase inhibitors, which could lead to excessive opioid peptide accumulation.

Use with caution

• Co‑administration with drugs that affect renal clearance (e.g., aminoglycosides, NSAIDs) may alter racecadotril elimination.
• Concurrent use of anticholinergic agents that also reduce intestinal motility.
• Overlapping use with other antidiarrheal agents such as loperamide, which may increase the risk of constipation.
• Patients on medications metabolized by hepatic enzymes should be monitored for potential indirect effects.